BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
At least 36 dead in major fire in Hong Kong residential blocks - 2Opening Your True capacity: 12 Techniques for Personal growth
- 3Language Learning Stages: Which One Gets Your Vote?
- 4AI is providing emotional support for employees – but is it a valuable tool or privacy threat?
- 5Turning into a Distributed Writer: My Composing Process
- 5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- Which Brilliant Home Gadget Can't You Reside Without?
- Old photos misrepresented as aftermath of political party supporters' brawl in Bangladesh
- Top Breakfast Food: What's Your Morning Joy?
- Extraordinary Guinness World Records That Will Astound You
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- All that You Really want to Be familiar with Dental Inserts Facilities
- Vote in favor of your #1 sort of juice
- Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
